Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Abstract Background Benralizumab, a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor α, depletes eosinophils and basophils by enhanced antibody-dependent cell-mediated cytotoxicity. It demonstrated efficacy for patients with moderate to severe asthma and, in a Phase I...

Full description

Bibliographic Details
Main Authors: Sriram Sridhar, Hao Liu, Tuyet-Hang Pham, Gautam Damera, Paul Newbold
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Respiratory Research
Subjects:
Asthma
Basophils
Benralizumab
Blood
Chronic obstructive pulmonary disease
Eosinophils
Online Access:http://link.springer.com/article/10.1186/s12931-018-0968-8

Internet

http://link.springer.com/article/10.1186/s12931-018-0968-8

Similar Items